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Kidney stone disease is commonly seen in general practice in both 
children and adults. This review addresses the epidemiology, causes, 
pathogenesis, diagnosis and management of recurrent nephrolithiasis, 
and the data reviewed in this article are taken from experience gained 
from running a kidney stone clinic for 40 years, which culminated in 
the publication of an MD thesis entitled ‘The pivotal role of a kidney 
stone clinic in the management and prevention of recurrent calcium 
oxalate nephrolithiasis’.[1] The thesis is considerably more detailed 
than the review, and is available to those who wish to further their 
reading on the subject.
Epidemiology
Renal calculous disease was known in the days of Hippocrates 
(400 BCE). The era of the alchemists started in about 1200 BCE, and 
the barber surgeons from about  1400 - 1700  BCE. The alchemists 
diagnosed the causes of kidney disorders as well as kidney stones 
based on the colour, composition, odour and taste of multiple urine 
samples to which chemicals had been added. They were then able 
to ‘treat’ their patients. The victims of the barber surgeons seldom 
survived after attempts to remove renal, ureteric and bladder calculi. 
Hence a saying proposed many years before by Hippocrates, ‘Thou 
shalt not cut for stone,’ was brought into law.[2] 
Stone disease is still one of the most common conditions seen in 
medical practice. It is associated with considerable mortality, chronic 
kidney disease (CKD) and occasionally even end-stage kidney 
disease (ESKD).[3-5] In 2001, nephrolithiasis was estimated to occur 
in about 12% of males and 5% of females. Multiple recurrences were 
seen in ~50% of these individuals.[6,7] Calcium oxalate (CaOx) calculi 
have been found to be the cause of stones in >80% of stone patients, 
and are frequently recurrent. Renal CaOx calculi occur in 85% of 
cases, and in the other 15%, calcium phosphate (CaP) comprises the 
chemical make-up. These CaP calculi occasionally cause ESKD. 
CaOx calculi are rare in the South African (SA) black population 
and in African Americans. The introduction of Westernised diets in 
recent years is expected to increase stone formation, but by a small 
margin only. As has been shown in African Americans, genetic 
factors occur that significantly inhibit the precipitation of CaOx 
in the urine. Although not yet studied in the black SA population, 
similar genetic findings remain a distinct possibility.[8-10] Moreover, 
as the years progress, so does stone incidence increase – especially 
in children. This is well illustrated in Fig. 1, and the epidemiological 
causes are for further reading, as discussed in the references.[11-14]
Note:
• There has been an increase in incidence in all age groups – mostly 
in those aged 10 - 19 years (23%).
• The mean incidence in African Americans is 15% (stone type not 
specified). 
• There are no data in black South Africans. CaOx calculi are still 
rare (~1%).[11]
Causes of nephrolithiasis
Major risk factors related to stone formation are shown in Fig. 2. 
These can include medullary sponge kidney, horseshoe kidney and 
autosomal dominant polycystic kidney disease.
These factors interact with one another, and are self-explanatory. 
The general aspects of different types of stone are shown in Table 1. 
This table clearly indicates how important it is to have the kidney 
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Fig. 1. Percentage changes in incidence of stone formation according to age 
groups. (Data extracted from Tasian et al.[11]) 
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stone chemically analysed. It is recommended that all first stones 
be analysed, and on one or occasionally two occasions, recurrent 
calculi should also be analysed. Stone analysis is often omitted by 
practitioners.
The causes of secondary stones are shown in Table 2. 
Pathogenesis of nephrolithiasis
Stone formation is a multistep process comprising crystal nucleation, 
growth, aggregation and finally, agglomeration.[21-26] It is a highly 
complex process, and only the basic steps are illustrated in Figs 3 
and 4. 
There are three steps in the process of crystallisation. Before a stone 
is formed, either nuclei or aggregates of nuclei must stick together. 
This is the process of crystallisation, and depends on the composition 
and concentration of urinary solutes. Then they must enlarge to form 
an agglomerate (i.e. a microcalculus). This process is ordered by the 
chemical process of ‘epitaxy’ (sticking together) in stone formers’ 
urines. CaOx stones can also form in association with ‘hyperuricosuria’ 
when epitaxy is absent; ‘salting out’ is the mechanism.[7] 
Metastable limit can also be lower in acid urines (pH <5.5). This is 


















Fig. 2. The major general risk factors in the development of kidney stones. 
(Reproduced with permission from Meyers.[1])
Table 1. General aspects related to the formation of different types of renal calculi[15-20]
Stone type Urinary risk factor Clinical aspect 
Calcium oxalate monohydrate Hypercalciuria Idiopathic
Salt excess
Hyperparathyroidism
Excess vitamin D 
Sarcoid and other granulomas
Genetic (e.g. Cushing’s disease,







Calcium phosphate As for calcium oxalate monohydrate
Distal renal tubular acidosis
Drugs, e.g. acetazolamide, topiramate
Struvite Ammonium (NH4) and bicarbonate (HCO3) Urinary tract infections (urea-splitting organisms)
Cystine Cystinuria Genetic (all four subtypes)
Table 2. Important secondary causes of nephrolithiasis[15-20]
Cause Biochemical change
Primary hyperparathyroidism Hypercalcaemia/hypercalciuria
Sarcoidosis Hypercalcaemia (10%), hypercalciuria (80%)
Other granulomas Hypercalcaemia, hypercalciuria
Genetic
Primary hyperoxaluria (all three subtypes) Hyperoxaluria (>1 000 µmol/24 hours)
Cystinuria Cystine and other dibasic amino acidurias
Tubulopathies Hyper/normocalcaemia, hypomagnesaemia, hypomagnesuria, 
hypocalciuria





Hyperoxaluria, hypocitraturia, hyperuricaemia, hyperuricosuria, low 
urine volume, hypomagnesaemia and hypomagnesuria
Post-bariatric surgery Hyperoxaluria
Cushing’s syndrome (primary or post-steroid ingestion) Hypercalcaemia/hypercalciuria
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the technique of salting out, even in the presence of adequate levels 
of other inhibitors.
These steps, as illustrated, are modified by factors that either 
promote or inhibit stone formation, as shown in Table 3. Major 
metabolic and mineral pathogenic factors are discussed in both groups.
Promotion
Of all the multiple factors, adequate water intake plays a pivotal role. 
Dehydration from any cause of water deprivation will render the 
urine lithogenic, while a good urine output (at least 2.4 L per day in 
recurrent stone formers) will constitute a significant inhibitory force. 
Fig. 5 demonstrates the effect of a low sodium diet on the 24-hour 
urinary calcium excretion.
The sources of dietary salt excess are dealt with under the 
management section (part 2). Basically, the World Health Organization 
recommends a daily sodium chloride intake of 5 - 5.5 g per day. This 
would ensure that the 24-hour urinary sodium excretion would be 
in the region of 80 - 100 mmol. Unfortunately, modern man is under 
such marketing persuasion that the usual excretion is 140 - 180 mmol 
per 24 hours. Stone formers’ excretions are often much higher, and 
even exceed 300 mmol per day. We are ‘pickling ourselves in brine’. 
The other important promotors are calcium (Ca) (hypercalciuria), 
hyperuricosuria and hyperoxaluria. By far the most common cause of 
hypercalciuria is an excessive amount of dietary salt.
Of pivotal importance in CaOx stone formation is the effect 
that urinary uric acid has on CaOx precipitation. By increasing the 
concentration of urinary uric acid, the uric acid will precipitate CaOx 
crystal formation via a chemical mechanism called salting out.[27] 
Simplistically, the uric acid acts as a catalyst for CaOx precipitation to 
form CaOx stones. If the urine is acid (as is common in the red meat-
eating population), this salting out can occur even with normal urinary 
uric acid concentrations. There is a large body of research to suggest 
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Supersaturation but metastable 
because of inhibitors, i.e. no stone 
formation because of inhibitors
Undersaturated urine – 
no stones or crystal aggregation
Fig. 4. Precipitation of calcium oxalate crystals with stone formation in 
either whole urine or a similarly manufactured solution. (CaOx = calcium 
oxalate; FP = formulation product; MSL = metastable limit; SP = saturation 
product.) (Reproduced with permission from Meyers and Martins.[7])
Fig. 5. 24-hour urine sodium and calcium in recurrent calcium stone 
formers pre- and post-standard (i.e. ‘healthy’) sodium diet (100 mmol/day). 
















Table 3. Promotors and inhibitors of stone formation[6]
Promotor Inhibitor





Failure of adequate intake
Global and regional climate change Organic
Nephrocalcin
F-1 fragment of prothrombin
Sulphated glycosaminoglycans 
Tetrahydropalmatine (Tamm-Horsfall protein)






Bacterial products (not for recurring calcium oxalate stone formation)
Proton pump inhibitors
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This applies whether or not there is hyperuricaemia, which is always 
associated with even a mild rise in the urinary uric acid concentration 
(which could occur if the patient were dehydrated).[28,29] 
Inhibition
The role of water in urinary dilution has already been mentioned. 
Hypomagnesaemia and hypomagnesuria may occasionally be found 
in children with genetic renal dysfunction, e.g. renal tubular acidosis 
(RTA), or in secondary causes of tubular dysfunction. Magnesium is 
a potent inhibitor of CaOx precipitation and plays an important role 
in these patients and in stone formation.
In the white SA population, a decrease of the 24-hour urinary citrate 
level is by far the most common pathogenetic factor in the production 
of recurrent CaOx (RCaOx) stone disease. This has not been found in 
black South Africans.[30] Other secondary risk factors for hypocitraturia 
include diets low in potassium, and any cause (whether primary or 
secondary) of RTA. Of importance is the RTA associated with the use 
of acetazolamide and topiramate (Topamax).[31]
Other factors in the pathogenesis of CaOx stone 
formation
Several dietary factors exist, which will be dealt with under the 
section on management (part 2).
There is a definite association between obesity and CaOx stone 
formation. This may in part be ascribed to dietary indiscretion, but 
other metabolic factors also play an important role.[32-35]
The frequent presence of Randall’s plaques in recurrent stone 
formers is an important epidemiological as well as pathogenetic 
factor in the production of recurrent stone formation.[36-43] Randall’s 
plaques increase in number and form in the tips of the papillae 
in recurrent stone formers. They are diagnosed by radiological 
techniques. In the black population of SA, Randall’s plaques seem to 
be far less frequent or almost absent, but future studies are required to 
confirm these observations. This is yet another reason for decreased 
stone formation in black patients. 
The frequent misuse of antibiotics, especially in children, has been 
shown to be a risk factor in CaOx stone production.[14] 
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